Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 11/20 | 0.41 |
| ▸ | PRKACA | P17612 | 11/20 | 0.41 |
| ▸ | PIM1 | P11309 | 10/20 | 0.41 |
| ▸ | GSK3B | P49841 | 10/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 10/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.41 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.41 |
| ▸ | CDK7 | P50613 | 6/20 | 0.40 |
| ▸ | CDK9 | P50750 | 6/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 5/20 | 0.39 |
| ▸ | CLK2 | P49760 | 5/20 | 0.39 |
| ▸ | PRKX | P51817 | 5/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.39 |
| ▸ | CDK8 | P49336 | 4/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21873076 | 0.83 | CDC7 (0.43) | MAP2K1CDC7PRKACAPIM1GSK3B | |
| SCHEMBL21872999 | 0.80 | MAP2K1 (0.41) | MAP2K1CDC7PRKACAPIM1GSK3B | |
| SCHEMBL21872985 | 0.76 | HDAC3 (0.39) | CDC7PRKACAPIM1GSK3BHIPK2 | |
| SCHEMBL12251765 | 0.75 | MAP2K1 (0.42) | MAP2K1CDC7PRKACAPIM1GSK3B | |
| SCHEMBL1267530 | 0.75 | MAP2K1 (0.42) | MAP2K1CDC7PRKACAPIM1GSK3B | |
| SCHEMBL1267762 | 0.73 | HDAC3 (0.38) | MAP2K1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL857798 | 0.73 | AXL (0.48) | MAP2K1DYRK1ALRRK2AXLFGFR1 | |
| SCHEMBL28339596 | 0.72 | CSF1R (0.44) | MAP2K1CDC7PRKACAPIM1GSK3B | |
| SCHEMBL857532 | 0.72 | MAP2K1 (0.41) | MAP2K1CDC7PRKACAPIM1GSK3B | |
| SCHEMBL19471778 | 0.70 | HDAC3 (0.45) | MAP2K1CDC7PRKACAPIM1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| CN-110461841-B | Nitrogen heteroaryl derivative with CSF1R inhibitory activity, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| CN-110461841-A | A kind of azepine aryl derivatives, preparation method and application with CSF1R inhibitory activity | ABBISKO THERAPEUTICS CO LTD | 2019-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSF1R, CSF3R, FSHR | MAP2K1 2519/4885CDC7 2303/4885PRKACA 2165/4885 |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | CSF1R, CSF3R, FSHR | MAP2K1 2519/4885CDC7 2303/4885PRKACA 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.